Table 3.
Secondary efficacy outcomes, Uganda therapeutic efficacy monitoring 2018–2019
| Secondary Efficacy outcome | Kwania district | Arua district | Busia district | |||
|---|---|---|---|---|---|---|
| AL | DP | AL | DP | AL | DP | |
| Parasitemia prevalence n (%) | ||||||
| Day 1 | 72 (69.2) | 65 (68.4) | 98 (99.0) | 88 (91.7) | 93 (91.2) | 75 (79.8) |
| Day 2 | 14 (13.5) | 11 (11.6) | 46 (46.5) | 31 (32.3) | 9 (8.8) | 7 (7.5) |
| Day 3 | 0 (0.0) | 1 (1.1) | 3 (3.0) | 2 (2.1) | 0 (0.0) | 0 (0.0) |
| Fever prevalence n (%) | ||||||
| Day 1 | 2 (1.96) | 4 (4.2) | 6 (6.13) | 9 (9.3) | 5 (4.9) | 2 (2.1) |
| Day 2 | 0 (0.0) | 1 (1.1) | 0 (0.0) | 1 (1.0) | 4 (3.9) | 0 (0.0) |
| Day 3 | 0 (0.0) | 1 (1.1) | 0 (0.0) | 0 (0.0) | 2 (2.0) | 0 (0.0) |
| Gametocyte prevalence n (%) | ||||||
| Day 1 | 1 (1.0) | 1 (1.1) | 4 (4.0) | 6 (6.3) | 11 (10.8) | 15 (16.0) |
| Day 2 | 0 (0.0) | 1 (1.1) | 4 (4.0) | 6 (6.3) | 5 (4.9) | 13 (13.8) |
| Day 3 | 0 (0.0) | 0 (0.0) | 3 (3.0) | 6 (6.3) | 3 (2.9) | 12 (12.8) |
| Day 4–28 (AL) or 42 (DP) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) | 1 (0.1) |
AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine